Clinical trials and research studies

MOVR:  Data Hub is the first and only data hub that aggregates clinical, genetic, and patient reported data for multiple nuromuscular diseases.  Collection of patient data about disease progression in the era of new treatments will inform and accelerate future innovation.  The combination of data collected through MOVR Data Hub will provide a comprehensive understanding of health and patient experiences in a single data repository.  MOVR Data Hub has the power to transform health outcomes, accelerate drug development and drive clinical research across multiple neuromuscular diseases, helpin

ANNEXa-1 (18-513): This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracerebral hemorrhage within 6 hours of symptom onset (from the baseline scan) and within 15 hours of taking an oral FXa inhibitor (from randomization). The study will use a prospective, randomized, open-label design, as it is unfeasible to blind the Investigator to the treatment assignment given the many potential therapeutic options available under usual care treatment.